NCT06462222View on ClinicalTrials.gov

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

January 30, 2026

Study Completion Date

July 30, 2026

Conditions
Leptomeningeal Metastasis
Interventions
DRUG

Toripalimab, pemetrexed

Drug 1: Toripalimab 40 mg; Drug 2: pemetrexed 15mg. intrathecal injection therapy

Trial Locations (1)

516000

The Affiliated Huizhou Hospital, Guangzhou Medical University, Huizhou

All Listed Sponsors
lead

Guangzhou Medical University

OTHER

NCT06462222 - Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors | Biotech Hunter | Biotech Hunter